Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622
This examiner grants 57% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18248124 | USE OF AN ERK INHIBITOR FOR THE TREATMENT OF MYELOFIBROSIS | Non-Final OA | University of Basel |
| 17621057 | HCK DEGRADERS AND USES THEREOF | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 17284250 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 18023318 | DOSING SCHEDULE FOR A METHOD OF TREATMENT WITH DHODH INHIBITORS | Final Rejection | Bayer Aktiengesellschaft |
| 18011637 | Combination Verapamil and Mometasone Therapy for the treatment of Chronic Rhinosinusitis | Non-Final OA | Massachusetts Eye and Ear Infirmary |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy